Chimeric siRNA-DNA Surfactants for the Enhanced Delivery and Sustained Cytotoxicity of a Gold(III) Metallodrug.

Bioconjugate Chemistry
Alyssa K HartmannJessica L Rouge

Abstract

Using a recently developed nucleic acid delivery platform, we demonstrate the effective delivery of metallodrug [AuIIIBr2(SSC-Inp-OEt)] (AP228; Inp = isonipecotic moiety), a hydrophobic, low solubility gold complex cytotoxic to cancer cells. It is shown that AP228 is delivered more effectively into HeLa cells using micellular surfactant assemblies compared to that of a more polar derivative [AuIIIBr2(SSC-Inp-GlcN1)] (AP209; GlcN1 = (α,β)-d-glucosamino moiety). When AP228 is codelivered with siRNA targeting Bcl-2, a key regulator of apoptosis, the overall cytotoxic therapeutic effects of the drug are maximized. The optimized delivery and distribution of the compound is monitored by both fluorescence microscopy and inductively coupled plasma mass spectrometry. We show that codelivery of the AP228 and Bcl-2 targeting siRNA results in a substantial increase in drug efficacy, wherein the cytotoxic therapeutic effects of the drug are maximized, reducing the IC50 from 760 nM to 11 nM. This hybrid small molecule drug and therapeutic nucleic acid delivery vehicle is shown to enable both the improved solubility and uptake of the gold(III) metallodrugs and the delivery of chemically unmodified siRNA, resulting in enhanced cytotoxic effects.

References

Jan 1, 1994·The Journal of Cell Biology·J C Reed
Jul 20, 2002·Biological Research·Rodolfo A Medina, Gareth I Owen
Aug 11, 2007·International Journal of Cancer. Journal International Du Cancer·Emmanuelle WesargMartin Schuler
Dec 10, 2009·The Journal of Veterinary Medical Science·Yuzuru WatanabeHiroshi Kamata
Feb 27, 2010·Anti-cancer Agents in Medicinal Chemistry·Luca RonconiDolores Fregona
Sep 21, 2010·International Journal of Cancer. Journal International Du Cancer·Cristina MarzanoDolores Fregona
Jan 20, 2012·Journal of the American Chemical Society·Sandani SamarajeewaKaren L Wooley
Aug 31, 2012·Mini Reviews in Medicinal Chemistry·Eszter Márta NagyDolores Fregona
Jul 25, 2014·European Journal of Pharmacology·Shaloam Dasari, Paul Bernard Tchounwou
Jul 17, 2015·Advanced Materials·Cassandra E CallmannNathan C Gianneschi
Dec 16, 2016·Expert Opinion on Therapeutic Patents·Baoxin ZhangJianguo Fang
Apr 26, 2017·Journal of the American Chemical Society·Joseph K AwinoJessica L Rouge
Oct 11, 2017·Chemical Science·Danny BousmailHanadi F Sleiman
Feb 20, 2018·Molecular Therapy : the Journal of the American Society of Gene Therapy·Xinyi WangYi Ba
Jun 5, 2018·Chembiochem : a European Journal of Chemical Biology·Alyssa K HartmannJessica L Rouge
Jun 27, 2018·Dalton Transactions : an International Journal of Inorganic Chemistry·Andrea PettenuzzoLuca Ronconi
Dec 14, 2018·International Journal of Molecular Sciences·Marilina García-ArandaMaximino Redondo
Mar 19, 2019·Trends in Biotechnology·Saketh GudipatiJessica L Rouge

❮ Previous
Next ❯

Citations

Oct 24, 2020·ACS Combinatorial Science·Milad AshrafizadehPooyan Makvandi
Mar 30, 2021·Frontiers in Chemistry·Ina F de la FuenteJessica L Rouge
Jun 11, 2021·Dalton Transactions : an International Journal of Inorganic Chemistry·Andrea PettenuzzoLuca Ronconi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.